<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-10.anc" start="16971" end="16976" sStart="16952" offset="19" sid="r7.1.use.v.0067" wn="1" wnkey="use%2:34:01::" annotator="veweser" text="Virologic findings using the more stringent virologic suppression endpoint of HIV-1 RNA &lt;50 copies/mL paralleled those with the &lt;200 copies/mL endpoint, although differences attained statistical significance." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-10.anc" start="6262" end="6268" sStart="null" offset="343" sid="r9.normal.j.0130" wn="2" wnkey="normal%3:00:02::" annotator="anfahmy" text="Patients were excluded if they had active Centers for Disease Control (CDC) Class C status; could not comply with the study schedule; were in another investigational drug study; were undergoing opiate detoxification; had a malabsorption syndrome or pre-existing condition that interfered with normal gastrointestinal transit; had clinically significant laboratory abnormalities, required radiation therapy or cytotoxic chemotherapy, or had received immunomodulating agents, within 4 weeks pre-study; or had received an HIV-1 immunotherapeutic vaccine within 3 months pre-study." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-10.anc" start="25744" end="25749" sStart="null" offset="133" sid="null" wn="1" wnkey="level%1:07:00::" annotator="veweser" text="The 24-week extension phase showed that most patients who had HIV-1 RNA &lt;200 copies/mL at week 24 maintained this level of virologic suppression through week 48." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-10.anc" start="25744" end="25749" sStart="null" offset="133" sid="null" wn="1" wnkey="level%1:07:00::" annotator="sophiavv" text="The 24-week extension phase showed that most patients who had HIV-1 RNA &lt;200 copies/mL at week 24 maintained this level of virologic suppression through week 48." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-10.anc" start="25744" end="25749" sStart="null" offset="133" sid="null" wn="1" wnkey="level%1:07:00::" annotator="cgozo" text="The 24-week extension phase showed that most patients who had HIV-1 RNA &lt;200 copies/mL at week 24 maintained this level of virologic suppression through week 48." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-10.anc" start="25744" end="25749" sStart="null" offset="133" sid="null" wn="1" wnkey="level%1:07:00::" annotator="brubin" text="The 24-week extension phase showed that most patients who had HIV-1 RNA &lt;200 copies/mL at week 24 maintained this level of virologic suppression through week 48." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-10.anc" start="13907" end="13912" sStart="null" offset="230" sid="r9.level.n.0948" wn="2" wnkey="level%1:26:01::" annotator="brubin" text="A total of 211 patients enrolled; they were predominantly male (87%), ethnically diverse (48% Caucasian, 37% African American, 14% Hispanic), and had a mean age of 42 years, median baseline HIV-1 RNA level of 4.33 log 10 copies/mL, and median baseline CD4+ cell count of 257 cells/mm 3. Most of the study population was antiretroviral-experienced (81%)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-10.anc" start="19804" end="19810" sStart="null" offset="31" sid="r9.level.n.0724" wn="2" wnkey="level%1:26:01::" annotator="brubin" text="In these 3 patients, HIV-1 RNA levels ranged from 316 to 3645 copies/mL, 1247 to 5175 copies/mL, and 143 to 12,149 copies/mL, respectively, between weeks 24 and 48." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-10.anc" start="28924" end="28930" sStart="null" offset="238" sid="r9.level.n.0596" wn="2" wnkey="level%1:26:01::" annotator="brubin" text="One limitation of our study was that no pharmacokinetic analyses were performed to validate whether the RTV dosage regimen co-administered with APV600 was effectively boosting plasma APV exposure or C min levels." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-10.anc" start="25744" end="25749" sStart="null" offset="133" sid="null" wn="" wnkey="null" annotator="bpassonneau" text="The 24-week extension phase showed that most patients who had HIV-1 RNA &lt;200 copies/mL at week 24 maintained this level of virologic suppression through week 48." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-10.anc" start="25744" end="25749" sStart="null" offset="133" sid="null" wn="1" wnkey="level%1:07:00::" annotator="anfahmy" text="The 24-week extension phase showed that most patients who had HIV-1 RNA &lt;200 copies/mL at week 24 maintained this level of virologic suppression through week 48." />
  </sentences>
</list>